Chris Twelves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chris Twelves has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Jim Cassidy
3 shared publicationsA. Anthoney
2 shared publicationsJ. Wanders
2 shared publicationsA Anthoney
1 shared publicationA Awada
1 shared publicationA. Bowman
1 shared publication
Latest Publications
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi543
5-Fluorouracil (5FU) intratumoural pharmacokinetics: Rapid uptake in cells and in spheroids (SPH)
Background: Limited data are available on 5FU intratumoral pharmacokinetics. Previous studies with radiolabeled 5FU showed homogeneous uptake in spheroids within a few minutes (Cancer Chemother Pharmacol. 1984;13(2):131-5) but no quantification was done. We present data on intracellular and intra-spheroidal 5FU uptake; drug efflux experiments are on-going and results will be presented.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi543
5-Fluorouracil (5FU) intratumoural pharmacokinetics: Rapid uptake in cells and in spheroids (SPH)
Background: Limited data are available on 5FU intratumoral pharmacokinetics. Previous studies with radiolabeled 5FU showed homogeneous uptake in spheroids within a few minutes (Cancer Chemother Pharmacol. 1984;13(2):131-5) but no quantification was done. We present data on intracellular and intra-spheroidal 5FU uptake; drug efflux experiments are on-going and results will be presented.
- 4 June 2013
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 10 (02) , A21
Lebensqualität von Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen unter der Behandlung mit Eribulin oder Capecitabin: eine randomisierte, unverblindete Phase III-Studie
Poster Retreat vom ASCO 2013. Zielsetzung: Eine Phase III-Studie zum Vergleich Eribulin (E) gegen Capecitabin (C) bei Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs (mBC) konnte keine statistisch signifikante Überlegenheit hinsichtlich PFS oder OS zeigen. Die Verträglichkeitsprofile entsprachen bekannten Nebenwirkungen. Hier werden die Lebensqualitätsdaten (QoL) vorgestellt. Materialien und Methoden: Patientinnen erhielten entweder 1,23 mg E/m2 an Tag 1 und 8 oder C 1,25 g/m2 2x täglich p.o. an Tag 1 – 14 in einem 21 Tage Zyklus. Patientinnen mussten vorherige Behandlung mit Anthrazyklin oder Taxan erhalten haben und erhielten die Studienmedikamente als Erst-, Zweit-, oder Drittlinientherapie für fortgeschrittene Erkrankung. Lebensqualität wurde als sekundärer Endpunkt mittels EORTC QLQ-C30 und QLQ-BR23 Fragebögen bei Studienbeginn, nach 6 Wochen, 3, 6, 12, 18 und 24 Monaten nach Behandlungsbeginn (oder bis Progression/Therapiewechsel) sowie bei ungeplanten Studienvisiten bestimmt. Longitudinale Analysen wurden anhand von gewichteten allgemeinen Schätzfunktionen durchgeführt, wobei für nicht-zufällige Abgänge durch Lebensverlust innerhalb von 12 Monaten adjustiert wurde. Covariate Faktoren waren die Zeit (Studienvisite), Region und Lebensqualität bei Studienbeginn. Primärer Endpunkt: Veränderung versus Baseline des Global Health Status (GHS/QoL insgesamt); explorativ: Änderung versus Studienbeginn für einzelne Funktionsbereiche und Parameter/Symptome. Ergebnisse: 1102 randomisierte Patientinnen (E 554; C 548) mit niedrigen GHS/QoL Scores (E 56,3; C 54,7 [100 = beste QoL zeigten unter E signifikant stärkere Besserung von GSH/QoL und kognitiver Funktion (E vs. C 6,5 [p = 0,048] bzw. 15,3 [p < 0,001]. C zeigte für emotionale Funktionalität signifikant stärkere Besserung (C vs. E 3,3 [p = 0,033]). Die Stärke von Schmerzen zu Studienbeginn und Abnahme unter Therapie war vergleichbar für E und C. Patienten berichteten unter E von weniger Anzeichen/Symptomen wie Übelkeit und Erbrechen (-1,9; p = 0,043) und Diarrhö (-3,7; p = 0,001). Unter C wurden weniger systemische unerwünschte Wirkungen (5,2; p < 0,001) und Probleme mit Haarverlust berichtet (9,3; p = 0,023). Zusammenfassung: GHS/QoL Scores verbesserten sich stärker bei Patienten unter E als C. Eribulin zeigte Vorteile hinsichtlich gastrointestinaler Effekte, C zeigte Vorteile hinsichtlich Haarverlust.
- 4 June 2013
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 10 (02) , A21
Lebensqualität von Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen unter der Behandlung mit Eribulin oder Capecitabin: eine randomisierte, unverblindete Phase III-Studie
Poster Retreat vom ASCO 2013. Zielsetzung: Eine Phase III-Studie zum Vergleich Eribulin (E) gegen Capecitabin (C) bei Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs (mBC) konnte keine statistisch signifikante Überlegenheit hinsichtlich PFS oder OS zeigen. Die Verträglichkeitsprofile entsprachen bekannten Nebenwirkungen. Hier werden die Lebensqualitätsdaten (QoL) vorgestellt. Materialien und Methoden: Patientinnen erhielten entweder 1,23 mg E/m2 an Tag 1 und 8 oder C 1,25 g/m2 2x täglich p.o. an Tag 1 – 14 in einem 21 Tage Zyklus. Patientinnen mussten vorherige Behandlung mit Anthrazyklin oder Taxan erhalten haben und erhielten die Studienmedikamente als Erst-, Zweit-, oder Drittlinientherapie für fortgeschrittene Erkrankung. Lebensqualität wurde als sekundärer Endpunkt mittels EORTC QLQ-C30 und QLQ-BR23 Fragebögen bei Studienbeginn, nach 6 Wochen, 3, 6, 12, 18 und 24 Monaten nach Behandlungsbeginn (oder bis Progression/Therapiewechsel) sowie bei ungeplanten Studienvisiten bestimmt. Longitudinale Analysen wurden anhand von gewichteten allgemeinen Schätzfunktionen durchgeführt, wobei für nicht-zufällige Abgänge durch Lebensverlust innerhalb von 12 Monaten adjustiert wurde. Covariate Faktoren waren die Zeit (Studienvisite), Region und Lebensqualität bei Studienbeginn. Primärer Endpunkt: Veränderung versus Baseline des Global Health Status (GHS/QoL insgesamt); explorativ: Änderung versus Studienbeginn für einzelne Funktionsbereiche und Parameter/Symptome. Ergebnisse: 1102 randomisierte Patientinnen (E 554; C 548) mit niedrigen GHS/QoL Scores (E 56,3; C 54,7 [100 = beste QoL zeigten unter E signifikant stärkere Besserung von GSH/QoL und kognitiver Funktion (E vs. C 6,5 [p = 0,048] bzw. 15,3 [p < 0,001]. C zeigte für emotionale Funktionalität signifikant stärkere Besserung (C vs. E 3,3 [p = 0,033]). Die Stärke von Schmerzen zu Studienbeginn und Abnahme unter Therapie war vergleichbar für E und C. Patienten berichteten unter E von weniger Anzeichen/Symptomen wie Übelkeit und Erbrechen (-1,9; p = 0,043) und Diarrhö (-3,7; p = 0,001). Unter C wurden weniger systemische unerwünschte Wirkungen (5,2; p < 0,001) und Probleme mit Haarverlust berichtet (9,3; p = 0,023). Zusammenfassung: GHS/QoL Scores verbesserten sich stärker bei Patienten unter E als C. Eribulin zeigte Vorteile hinsichtlich gastrointestinaler Effekte, C zeigte Vorteile hinsichtlich Haarverlust.
- Open Access
- 1 March 2013
- Published by Elsevier
- Vol. 24 (suppl 1) , i33-i35
Poster session 6. Phase 1 studies
- 1 March 2013
- Published by Elsevier
- Vol. 24 (suppl 1) , i33-i35
Open AccessPoster session 6. Phase 1 studies
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S331-S332
5006 ORAL Eribulin Mesylate EMBRACE Study – Survival Analysis Excluding Patients Re-challenged With Therapies of the Same Class
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S331-S332
5006 ORAL Eribulin Mesylate EMBRACE Study – Survival Analysis Excluding Patients Re-challenged With Therapies of the Same Class
- 1 November 2006
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 6 (4) , 278-287
Xeloda® in Adjuvant Colon Cancer Therapy (X-ACT) Trial: Overview of Efficacy, Safety, and Cost-Effectiveness
- 1 November 2006
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 6 (4) , 278-287
Xeloda® in Adjuvant Colon Cancer Therapy (X-ACT) Trial: Overview of Efficacy, Safety, and Cost-Effectiveness
- Open Access
- 12 December 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (2) , 239-245
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Background: Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i.v.) 5-fluorouracil/leucovorin (5-FU/LV). The tumour-activated, oral fluoropyrimidine capecitabine demonstrates superior activity and favourable safety compared with the Mayo regimen, while potentially avoiding the complications and inconvenience associated with i.v. regimens. Patients and methods: Ninety-seven patients with previously untreated advanced/MCRC were randomised to receive capecitabine followed by i.v. 5-FU/LV [Mayo Clinic, in-patient de Gramont (IPdG) or out-patient modified de Gramont (OPdG) regimens], or i.v. 5-FU/LV followed by capecitabine. Results: Before treatment, of those patients for whom a preference was recorded, almost all (95%) preferred oral treatment (consistent across all treatment groups) and the majority retained this preference after treatment (64% overall; 86%, 63% and 50% in the Mayo, IPdG and OPdG groups, respectively). Following treatment, the principal reasons for oral treatment preference were increased convenience, home-based administration and tablet formulation. Treatment satisfaction was significantly higher with capecitabine compared with Mayo (P P P Conclusions: This study confirmed that the majority of patients with MCRC prefer oral to i.v. therapy, although the OPdG regimen appears to be the most popular i.v. option. Capecitabine clearly represents an effective, well-tolerated oral alternative to i.v. 5-FU/LV.
- 12 December 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (2) , 239-245
Open AccessA randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Background: Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i.v.) 5-fluorouracil/leucovorin (5-FU/LV). The tumour-activated, oral fluoropyrimidine capecitabine demonstrates superior activity and favourable safety compared with the Mayo regimen, while potentially avoiding the complications and inconvenience associated with i.v. regimens. Patients and methods: Ninety-seven patients with previously untreated advanced/MCRC were randomised to receive capecitabine followed by i.v. 5-FU/LV [Mayo Clinic, in-patient de Gramont (IPdG) or out-patient modified de Gramont (OPdG) regimens], or i.v. 5-FU/LV followed by capecitabine. Results: Before treatment, of those patients for whom a preference was recorded, almost all (95%) preferred oral treatment (consistent across all treatment groups) and the majority retained this preference after treatment (64% overall; 86%, 63% and 50% in the Mayo, IPdG and OPdG groups, respectively). Following treatment, the principal reasons for oral treatment preference were increased convenience, home-based administration and tablet formulation. Treatment satisfaction was significantly higher with capecitabine compared with Mayo (P P P Conclusions: This study confirmed that the majority of patients with MCRC prefer oral to i.v. therapy, although the OPdG regimen appears to be the most popular i.v. option. Capecitabine clearly represents an effective, well-tolerated oral alternative to i.v. 5-FU/LV.
- 1 July 2005
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 5 (2) , 101-107
Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study
- 1 July 2005
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 5 (2) , 101-107
Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study
- Top Cited PapersOpen Access
- 30 June 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (26) , 2696-2704
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
- 30 June 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (26) , 2696-2704
Top Cited PapersOpen AccessCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
- 1 August 2004
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5 (3) , 216-222
Quality of Life in Women with Advanced Breast Cancer Treated with Docetaxel
- 1 August 2004
- Published by Elsevier in Clinical Breast Cancer
- Vol. 5 (3) , 216-222
Quality of Life in Women with Advanced Breast Cancer Treated with Docetaxel
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 2005
A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours
2005 Background: There is increasing evidence that DNA hypermethylation of CpG islands at key genes is associated with chemo resistance. For instance, methylation of a CpG-island at the hMLH1 promoter may be a major mechanism for loss of MLH1 expression associated with chemo resistance. Decitabine (5-Aza-2'-deoxycytidine) is a demethylating agent which has been shown in in vivo studies to reactivate MLH1 expression leading to sensitisation of chemo resistant tumours to a range of cytotoxic drugs. This Phase I study investigated the feasibility of delivering a dose of decitabine which would cause demethylation and hence potential sensitisation without causing prohibitive myelosuppression in combination with carboplatin. Methods: Pts with a variety of malignancies were enrolled. The starting dose of decitabine (on Day 1) was 45mg/m2. This was escalated in steps of 45mg/m2. Carboplatin at a fixed dose of AUC5 was given on Day 8. The interval between decitabine and carboplatin was 8 days which was within the optimal time for demethylation from xenograft studies. Treatment was repeated every 4 weeks. Results: 14 heavily-pretreated pts have been enrolled to date (6M/8F). Median age: 55; mean PS (ECOG): 1. Pts have been treated at 3 dose levels of decitabine: 45, 90 and 135mg/m2. Median number of cycles: 2 (range 0.5–6). 13/14 patients were evaluable for toxicity. MTD was identified as decitabine 135mg/m2 with grade 4 febrile neutropenia (1 pt), and grade 4 neutropenia necessitating delay of cycle 2 for >7 days (1 pt). Other possible treatment-related toxicities included: nausea, vomiting, diarrhoea, fatigue, anorexia, anaemia (all ≤grade 2 and easily manageable). PD studies showed reduction in 5-methylcytosine to total cytosine ratios in DNA isolated from peripheral mononuclear cells at all dose levels, and was maximal between Days 8 and 12 following decitabine infusion Conclusion: This study confirms that the combination of decitabine and carboplatin is feasible. Futher patients are being accrued to assess PD effects in tumour as well as peripheral blood and buccal smears. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 2005
A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours
2005 Background: There is increasing evidence that DNA hypermethylation of CpG islands at key genes is associated with chemo resistance. For instance, methylation of a CpG-island at the hMLH1 promoter may be a major mechanism for loss of MLH1 expression associated with chemo resistance. Decitabine (5-Aza-2'-deoxycytidine) is a demethylating agent which has been shown in in vivo studies to reactivate MLH1 expression leading to sensitisation of chemo resistant tumours to a range of cytotoxic drugs. This Phase I study investigated the feasibility of delivering a dose of decitabine which would cause demethylation and hence potential sensitisation without causing prohibitive myelosuppression in combination with carboplatin. Methods: Pts with a variety of malignancies were enrolled. The starting dose of decitabine (on Day 1) was 45mg/m2. This was escalated in steps of 45mg/m2. Carboplatin at a fixed dose of AUC5 was given on Day 8. The interval between decitabine and carboplatin was 8 days which was within the optimal time for demethylation from xenograft studies. Treatment was repeated every 4 weeks. Results: 14 heavily-pretreated pts have been enrolled to date (6M/8F). Median age: 55; mean PS (ECOG): 1. Pts have been treated at 3 dose levels of decitabine: 45, 90 and 135mg/m2. Median number of cycles: 2 (range 0.5–6). 13/14 patients were evaluable for toxicity. MTD was identified as decitabine 135mg/m2 with grade 4 febrile neutropenia (1 pt), and grade 4 neutropenia necessitating delay of cycle 2 for >7 days (1 pt). Other possible treatment-related toxicities included: nausea, vomiting, diarrhoea, fatigue, anorexia, anaemia (all ≤grade 2 and easily manageable). PD studies showed reduction in 5-methylcytosine to total cytosine ratios in DNA isolated from peripheral mononuclear cells at all dose levels, and was maximal between Days 8 and 12 following decitabine infusion Conclusion: This study confirms that the combination of decitabine and carboplatin is feasible. Futher patients are being accrued to assess PD effects in tumour as well as peripheral blood and buccal smears. No significant financial relationships to disclose.